Free shipping on all orders over $ 500
Bevacizumab is A humanized IgG1 monoclonal antibody that binds with high affinity and specificity to all VEGF-A.
| Cell Experiment | |
|---|---|
| Cell lines | NSCLC cell lines |
| Preparation method | Six NSCLC cell lines were seeded (~2,000–5,000 cells per well, depending on cell type) onto 96-well plates. After 24 h of incubation, cells were treated with erlotinib (0–20 µmol/L), bevacizumab (0–20 ng/mL) or a combination of these agents (erlotinib 1 µmol/L; bevacizumab 10 ng/mL) for 72 h in serum-containing medium. The viability was determined by MTS assay (Promega, Madison, WI) according to the manufacturer’s instructions. |
| Concentrations | 0–20 ng/mL |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | Female Wistar rats |
| Formulation | 0.9%sodium chloride solution |
| Dosages | 30 mg/kg |
| Administration | i.p. |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Molecular Weight | |
| Formula | |
| CAS Number | 216974-75-3 |
| Purity | >99% |
| Solubility | Water PBS |
| Storage | at -20°C |
[1] Liu W, et al. Eye Sci. Effect of Avastin on the migration and invasion of pterygium fibroblasts.
| Related VEGFR/PDGFR Products |
|---|
| TG 100801
TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. |
| Telatinib mesylate
Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active VEGFR2, VEGFR3, PDGFα, and c-Kit inhibitor with IC50s of 6 nM, 4 nM, 15 nM and 1 nM, respectively. |
| Lenvatinib mesylate
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. |
| Cediranib maleate
Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. |
| Pamufetinib
Pamufetinib (TAS-115) is a highly potent inhibitor of both C-MET and VEGFR, with IC50 of 30 nM and 32 nM against recombinant VEGFR2 and VEGFR, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
